Dr. Ashebir Gebru Woldeabezgi, MD

Dr. Woldeabezgi practices at University of Maryland Charles Regional Medical Center in La Plata, Maryland, part of University of Maryland Medical System.

Dr. Woldeabezgi's NPI, 1598794646, was assigned on July 1, 2006. Dr. Woldeabezgi holds District of Columbia license MD035472.

Dr. Woldeabezgi's primary practice is University of Maryland Charles Regional Medical Center, at 5 Garrett Avenue, La Plata, MD 20646 in Charles County. The practice phone is (301) 609-4265.

Dr. Woldeabezgi's primary practice is University of Maryland Charles Regional Medical Center in La Plata, Maryland, part of University of Maryland Medical System. Dr. Woldeabezgi is also affiliated with University of Maryland Medical Center. The medical group on file is Ashebir Woldeabezgi MD PC. Dmand AI also links Dr. Woldeabezgi to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Woldeabezgi practices, 4 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Woldeabezgi's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dmand AI has Dr. Woldeabezgi's licenses on file in 3 states: District of Columbia, Maryland and Virginia.

CMS data shows 4,180 Medicare services from Dr. Woldeabezgi across 8 procedure codes in 2024, for 578 Medicare patients. Medicare paid $308,547 for them.

CMS counts 578 Medicare patients who saw Dr. Woldeabezgi in 2024. The largest group is 75 to 84, with 182 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 36% are also on Medicaid. Their average risk score is 3.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Woldeabezgi's median patient age at 64, with 42% women.

In 2024, Dr. Woldeabezgi wrote 324 Medicare Part D claims for 44 patients. 57% of them were for generic drugs. CMS names the drug for 240 of them, across 9 drugs with 11 or more claims each, at $403,631 in total drug cost. In 2023, CMS named 217 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 17 out of 100 for Dr. Woldeabezgi for performance year 2024, reported individually. Dr. Woldeabezgi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 436 general payments to Dr. Woldeabezgi from 19 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 91% of the total. ViiV Healthcare Company paid the most, $1,747.